SG10201405408YA - Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases - Google Patents
Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseasesInfo
- Publication number
- SG10201405408YA SG10201405408YA SG10201405408YA SG10201405408YA SG10201405408YA SG 10201405408Y A SG10201405408Y A SG 10201405408YA SG 10201405408Y A SG10201405408Y A SG 10201405408YA SG 10201405408Y A SG10201405408Y A SG 10201405408YA SG 10201405408Y A SG10201405408Y A SG 10201405408YA
- Authority
- SG
- Singapore
- Prior art keywords
- mcp
- treatment
- pharmaceutical composition
- inflammatory diseases
- mediated inflammatory
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09425368 | 2009-09-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201405408YA true SG10201405408YA (en) | 2014-10-30 |
Family
ID=41722750
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012010302A SG178414A1 (en) | 2009-09-23 | 2010-09-03 | Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases |
| SG10201405408YA SG10201405408YA (en) | 2009-09-23 | 2010-09-03 | Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012010302A SG178414A1 (en) | 2009-09-23 | 2010-09-03 | Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9492542B2 (en) |
| EP (1) | EP2480224B1 (en) |
| JP (2) | JP2013505278A (en) |
| KR (1) | KR101774402B1 (en) |
| CN (1) | CN102573827B (en) |
| AR (1) | AR078307A1 (en) |
| AU (1) | AU2010297405B2 (en) |
| BR (1) | BR112012006149A2 (en) |
| CA (1) | CA2760180C (en) |
| CY (1) | CY1119125T1 (en) |
| DK (1) | DK2480224T3 (en) |
| EA (1) | EA021485B1 (en) |
| ES (1) | ES2637024T3 (en) |
| GE (1) | GEP20146067B (en) |
| HR (1) | HRP20171209T1 (en) |
| HU (1) | HUE033102T2 (en) |
| IL (1) | IL218001A (en) |
| LT (1) | LT2480224T (en) |
| MX (1) | MX347957B (en) |
| PL (1) | PL2480224T3 (en) |
| PT (1) | PT2480224T (en) |
| SG (2) | SG178414A1 (en) |
| SI (1) | SI2480224T1 (en) |
| UA (1) | UA108742C2 (en) |
| WO (1) | WO2011036047A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009109654A2 (en) | 2008-03-07 | 2009-09-11 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Novel 1-benzyl-3-hydroxymethyilindazole derivatives and use thereof in the treatment of diseases based on the expression mcp-1 and cx3cr1 |
| WO2009109616A2 (en) | 2008-03-07 | 2009-09-11 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Novel 1-benzil-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| US8999292B2 (en) | 2012-05-01 | 2015-04-07 | Translatum Medicus Inc. | Methods for treating and diagnosing blinding eye diseases |
| US11221321B2 (en) * | 2019-05-29 | 2022-01-11 | Imam Abdulrahman Bin Faisal University | Liquid chromatographic method for the simultaneous analysis of antihypertensive and antilipidemic agents and interactions thereof |
| CA3144861A1 (en) | 2019-06-25 | 2020-12-30 | Translatum Medicus, Inc. | Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0173481A3 (en) | 1984-08-06 | 1988-12-21 | The Upjohn Company | Peptides |
| MY103189A (en) | 1986-10-31 | 1993-05-29 | Pfizer | Nor-statine and nor-cyclostatine polypeptides |
| US4927807A (en) | 1987-10-06 | 1990-05-22 | Abbott Laboratories | Glaucoma treatment |
| IT1230441B (en) | 1989-02-07 | 1991-10-23 | Acraf | ETHERS OF THE INDAZOLE SERIES |
| CA2023099A1 (en) | 1989-09-04 | 1991-03-05 | Quirico Branca | Amino acid derivatives |
| US5209933A (en) | 1990-01-10 | 1993-05-11 | Syntex (U.S.A.) Inc. | Long acting calcium channel blocker composition |
| IE68045B1 (en) | 1990-05-11 | 1996-05-15 | Abbott Lab | Renin inhibitors |
| TW198712B (en) | 1991-04-17 | 1993-01-21 | Hoffmann La Roche | |
| IT1253703B (en) * | 1991-04-22 | 1995-08-23 | Angelini Francesco Ist Ricerca | USE OF ALCANOIC ACID METHODS OF INDAZOLE TO PREPARE AN ACTIVE DRUG IN THE TREATMENT OF AUTOIMMUNITARY DISEASES |
| MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
| US5994348A (en) * | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
| IT1276031B1 (en) | 1995-10-31 | 1997-10-24 | Angelini Ricerche Spa | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
| SE9600120D0 (en) | 1996-01-15 | 1996-01-15 | Astra Ab | Novel medical use |
| IT1293795B1 (en) * | 1997-07-28 | 1999-03-10 | Angelini Ricerche Spa | DRUG ACTIVE IN REDUCING THE PRODUCTION OF MCP-1 PROTEIN |
| US6268377B1 (en) | 1998-09-28 | 2001-07-31 | Merck & Co., Inc. | Method for treating androgen-related conditions |
| GB0111077D0 (en) | 2001-05-04 | 2001-06-27 | Biochemie Gmbh | Organic compounds |
| CA2445913A1 (en) | 2001-05-14 | 2003-10-29 | Merck & Co., Inc. | Method of treatment |
| US20030060500A1 (en) * | 2001-09-19 | 2003-03-27 | Francois Mach | Facilitating organ transplantation with statins (HMG-CoA reductase inhibitors) |
| US7183285B2 (en) | 2004-04-29 | 2007-02-27 | Pharmix Corp. | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
| US20070060549A1 (en) | 2004-08-10 | 2007-03-15 | Friesen Albert D | Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders |
| US20060046996A1 (en) | 2004-08-31 | 2006-03-02 | Kowa Co., Ltd. | Method for treating hyperlipidemia |
| EP1806137A4 (en) * | 2004-10-29 | 2011-03-30 | Kowa Co | Therapeutic agent for glomerular disease |
| CA2571462C (en) | 2006-02-07 | 2013-08-13 | Mochida Pharmaceutical Co., Ltd. | Composition for preventing recurrence of stroke |
| WO2008084504A2 (en) | 2007-01-12 | 2008-07-17 | Rubicon Research Private Limited | Pharmaceutical compositions of angiotensin ii receptor blockers |
| CN101668525A (en) * | 2007-03-01 | 2010-03-10 | 前体生物药物股份公司 | New use of glutaminyl cyclase inhibitors |
| WO2009109616A2 (en) | 2008-03-07 | 2009-09-11 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Novel 1-benzil-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| WO2009109654A2 (en) | 2008-03-07 | 2009-09-11 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Novel 1-benzyl-3-hydroxymethyilindazole derivatives and use thereof in the treatment of diseases based on the expression mcp-1 and cx3cr1 |
| KR101581828B1 (en) | 2008-03-07 | 2015-12-31 | 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 | Novel 1-Benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40 |
-
2010
- 2010-03-09 UA UAA201203482A patent/UA108742C2/en unknown
- 2010-09-03 WO PCT/EP2010/062979 patent/WO2011036047A1/en active Application Filing
- 2010-09-03 SI SI201031512T patent/SI2480224T1/en unknown
- 2010-09-03 US US13/497,175 patent/US9492542B2/en active Active
- 2010-09-03 HU HUE10747897A patent/HUE033102T2/en unknown
- 2010-09-03 KR KR1020127007411A patent/KR101774402B1/en active IP Right Grant
- 2010-09-03 CA CA2760180A patent/CA2760180C/en not_active Expired - Fee Related
- 2010-09-03 GE GEAP201012675A patent/GEP20146067B/en unknown
- 2010-09-03 LT LTEP10747897.6T patent/LT2480224T/en unknown
- 2010-09-03 EP EP10747897.6A patent/EP2480224B1/en active Active
- 2010-09-03 PL PL10747897T patent/PL2480224T3/en unknown
- 2010-09-03 SG SG2012010302A patent/SG178414A1/en unknown
- 2010-09-03 EA EA201270449A patent/EA021485B1/en not_active IP Right Cessation
- 2010-09-03 ES ES10747897.6T patent/ES2637024T3/en active Active
- 2010-09-03 DK DK10747897.6T patent/DK2480224T3/en active
- 2010-09-03 JP JP2012530204A patent/JP2013505278A/en active Pending
- 2010-09-03 CN CN201080042390.9A patent/CN102573827B/en not_active Expired - Fee Related
- 2010-09-03 BR BR112012006149A patent/BR112012006149A2/en not_active Application Discontinuation
- 2010-09-03 MX MX2012003485A patent/MX347957B/en active IP Right Grant
- 2010-09-03 AU AU2010297405A patent/AU2010297405B2/en not_active Ceased
- 2010-09-03 SG SG10201405408YA patent/SG10201405408YA/en unknown
- 2010-09-03 PT PT107478976T patent/PT2480224T/en unknown
- 2010-09-22 AR ARP100103447A patent/AR078307A1/en unknown
-
2012
- 2012-02-09 IL IL218001A patent/IL218001A/en not_active IP Right Cessation
-
2015
- 2015-07-31 JP JP2015152596A patent/JP6122470B2/en active Active
-
2017
- 2017-07-28 CY CY20171100808T patent/CY1119125T1/en unknown
- 2017-08-07 HR HRP20171209TT patent/HRP20171209T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL257581A (en) | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| HK1163500A1 (en) | Pharmaceutical composition for the treatment of heart diseases | |
| PT2482812T (en) | Therapeutic uses of pharmaceutical compositions | |
| HRP20141057T1 (en) | Novel compound useful for the treatment of degenerative and inflammatory diseases | |
| EP2564845A4 (en) | Diindolylmethane-based drug for the treatment of hyperplastic and inflammatory diseases | |
| ZA201200944B (en) | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders | |
| PT2429507T (en) | Phosphate-free pharmaceutical composition for the treatment of glaucoma | |
| GB0906159D0 (en) | Drug combination for the treatment of proteostatic diseases | |
| HK1171677A1 (en) | Composition for the treatment of hemorrhoids and related diseases | |
| IL218001A0 (en) | Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases | |
| LT2328553T (en) | Corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract | |
| EP2416803A4 (en) | New methods for treatment of inflammatory diseases | |
| IL200753A (en) | Pharmaceutical composition comprising ib-meca for the treatment of psoriasis | |
| IL219050A0 (en) | Pharmaceutical composition for the treatment of bladder disorders | |
| EP2767286A4 (en) | Oral pharmaceutical composition for the treatment of inflammatory gastrointestinal diseases | |
| IL202502A (en) | Cxcl11 for the treatment of inflammatory diseases |